Camrelizumab and palbociclib before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (camrelizumab and palbociclib) given before surgery to people with a type of esophageal cancer called squamous cell carcinoma. It aims to see if this approach can help shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal squamous cell cancer confirmed by biopsy.
- The main tumor is in the chest and can be removed with surgery (stage cT1b-T3N1-3M0 or cT3N0M0).
- You are between 18 and 75 years old and in fairly good health (ECOG 0-1).
- Your major organs (blood, lungs, liver, kidneys, heart) work normally.
- You are willing to have surgery and can give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ivonescimab combined with chemotherapy, given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This Phase 3 trial compares two ways of treating resectable esophageal squamous cell cancer: (1) camrelizumab plus chemotherapy before surgery versus (2) chemo-radiation. It aims to see whether adding camrelizumab before surgery can improve outcomes for people who are planned to have their tumor surgically removed.
This trial tests whether giving the immunotherapy drug camrelizumab together with chemotherapy before surgery can help people with esophageal cancer avoid needing full removal of the esophagus. It aims to preserve the esophagus while still treating the cancer effectively.
This trial tests a combination of two drugs (interferon gamma and camrelizumab) given before surgery for a certain type of esophageal cancer. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of immunotherapy (camrelizumab), chemotherapy, and a targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamour Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.